Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Radiotherapy is one of the most common countermeasures for treating a wide range of
tumors. However, the radioresistance of cancer cells is still a major limitation for …

Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected
patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for …

PURPOSE To provide precise age-specific risk estimates of cancers other than female
breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g BRCA1/2)-mutant
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …